Search Beyond News…

Capricor Therapeutics investors face a September 28, 2026 deadline to seek lead plaintiff status in a securities class action

Executive summary: Investors in Capricor Therapeutics were notified of a September 28, 2026 deadline to apply as lead plaintiff in a class action securities lawsuit concerning alleged misstatements. The deadline highlights potential legal and financial costs for the company and serves as a reminder of persistent securities‑fraud risks in the biotech sector.

Who is involved: Capricor Therapeutics (Nasdaq: CAPR), law firm Kahn Swick & Foti, former Louisiana Attorney General Charles C. Foti Jr., and affected shareholders.

Likely next: Shareholders must submit lead plaintiff applications by September 28, 2026; the court will thereafter consider appointing a lead plaintiff and may schedule further proceedings.

Kahn Swick & Foti, LLC, together with former Louisiana Attorney General Charles C. Foti Jr., issued a notice advising Capricor Therapeutics shareholders that they must submit lead plaintiff applications by the end of September if they wish to pursue the ongoing securities fraud lawsuit. The filing underscores the continued exposure of biotech firms to shareholder litigation over alleged disclosure shortcomings.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Sources

Related cases

Browse the full archive →